

Gene Section

Mini Review

CLDN4 (claudin-4)

Stefanie Ripka, Thomas M Gress

Abteilung Innere Medizin I, Universitätsklinikum Ulm, Robert Koch Str.8, 89081 Ulm, Germany

Published in Atlas Database: October 2005

Online updated version: <http://AtlasGeneticsOncology.org/Genes/CLDN4ID42975ch7q11.html>

DOI: 10.4267/2042/38288


This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.
© 2006 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Hugo: CLDN4

Other names: CPETR; CPETR1; WBSR8 (Williams-Beuren syndrome chromosome region 8 protein); hCPE-R, CPE-R (Clostridium perfringens enterotoxin receptor)

Location: 7q11.23



Probe(s) - Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics.

DNA/RNA

Description

Intronless; one exon spanning 1.68 kb.

Transcription

One transcript of 1.68 kb with 630 bp of coding sequence.

Protein

Description

The CLDN4 protein contains 209 amino acids and has a molecular weight of 22.1 kDa with four putative transmembrane segments. It directly interacts with TJP1/ZO-1, TJP2/ZO-2 and TJP3/ZO-3.

Expression

Claudin-4 is expressed in many fetal and adult tissues, predominantly in lung, intestine and kidney. Overexpressed in pancreatic, breast, ovarian, and prostate cancer.

Localisation

Integral membrane protein. Tight junction component.

Function

CLDN4 plays a major role in tight junction-specific obliteration of the intercellular space.

Homology

Belongs to the claudin family.

Implicated in

Williams-Beuren syndrom

Disease

Williams-Beuren syndrom (WBS) includes supravalvular aortic stenosis (SVAS), multiple peripheral pulmonary arterial stenoses, elfin face, mental and statural deficiency, characteristic dental malformation, and infantile hypercalcemia. It is associated with an autosomal dominant contiguous gene deletion involving genes from chromosome band 7q11.23, including CLDN4, elastin and LIM-kinase1. Haploinsufficiency for CLDN4 may be the cause of certain cardiovascular and musculo-skeletal abnormalities observed in the context of this disease.

Gastric cancer

Oncogenesis

Downregulated in gastric cancer. Absence of CLDN4 may play a role in the disruption of cell-to-cell adhesion in diffuse type gastric cancer and in a loss of differentiation.

Pancreatic cancer

Oncogenesis

Overexpressed in pancreatic cancer. Overexpression is predominantly observed in well-differentiated tumors with decreased metastatic potential.

Breast cancer**Oncogenesis**

Overexpressed in breast cancer and Paget's disease. Significance unclear.

Ovarian cancer**Oncogenesis**

CLDN4 is upregulated in ovarian tumors and cell lines and may represent a novel marker for this disease.

Squamous cell carcinoma and Bowen's disease**Oncogenesis**

Expression of claudin-4 is associated with keratinization in SCC and BD.

Prostate cancer**Oncogenesis**

Overexpressed in prostate cancer epithelium. Significance unclear.

References

Paperna T, Peoples R, Wang YK, Kaplan P, Francke U. Genes for the CPE receptor (CPETR1) and the human homolog of RVP1 (CPETR2) are localized within the Williams-Beuren syndrom deletion. *Genomics* 1998 Dec 15;54(3):453-459.

Morita K, Furuse M, Fujimoto K, Tsukita S. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. *Proc Natl Acad Sci USA* 1999 Jan 19;96(2):511-516.

Long H, Crean CD, Lee WH, Cummings OW, Gabig TG. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. *Cancer Res* 2001 Nov 1;61(21):7878-7881.

Michl P, Barth C, Buchholz M, Lerch MM, Rolke M, Holzmann KH, Menke A, Fensterer H, Giehl K, Löhner M, Leder G, Iwamura T, Adler G, Gress TM. Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. *Cancer Res* 2003 Oct 1;63(19):6265-6271.

Nichols LS, Ashfaq R, Iacobuzio-Donahue CA. Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. *Am J Clin Pathol* 2004 Feb;121(2):226-230.

Morita K, Tsukita S, Miyachi Y. Tight junction-associated proteins (occludin,ZO-1; claudin-1, claudin-4) in squamous cell carcinoma and Bowen's disease. *Br J Dermatol* 2004 Aug;151(2):328-334.

Nichols LS, Ashfaq R, Iacobuzio-Donahue CA. Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. *Am J Clin Pathol* 2004 Feb;121(2):226-230.

Soini Y. Claudins 2, 3, 4, and 5 in Paget's disease and breast carcinoma. *Hum Pathol* 2004 Dec;35(12):1531-1536.

Lee SK, Moon J, Park SW, Song SY, Chung JB, Kang JK. Loss of the tight junction protein claudin 4 correlates with histological growth pattern and differentiation in advanced gastric adenocarcinoma. *Oncol Rep* 2005 Feb;13(2):193-199.

Tokes AM, Kulka J, Paku S, Szik A, Paska C, Novak PK, Szilak L, Kiss A, Bogi K, Schaff Z. Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. *Breast Cancer Res* 2005;7(2):R296-305.

This article should be referenced as such:

Ripka S, Gress TM. CLDN4 (claudin-4). *Atlas Genet Cytogenet Oncol Haematol.*2006;10(2):77-78.
